Condition: Lung Cancer (NSCLC) · Sponsor: University Hospital, Essen
The primary objective of this study is to determine the feasibility of four weeks of preoperative antibody therapy with amivantamab. Amivantamab will be administered as monotherapy (stage 1), and combined with carboplatin/pemetrexed chemotherapy (stage 2). Study treatment is followed by standard of care surgery, and (if clinically indicated) standard of care adjuvant therapy (chemotherapy, radiotherapy, EGFR tyrosine kinase inhibitor therapy) in patients with early stage or locally advanced non-small-cell lung cancer harboring oncogenic EGFR mutations who are eligible for curative resection.
This description comes directly from the study's public registry record.
Martin Schuler, Prof. Dr. med. · +492017232011 · neopredictEGFR.umesz@uk-essen.de
Always discuss trial participation with your own doctor first.
| Jessa Ziekenhuis, Department of Pneumology | Hasselt, Belgium | Recruiting |
| Thoraxklinik Heidelberg gGmbH, Studienzentrum Thoraxonkologie | Heidelberg, Baden-Wurttemberg, Germany | Recruiting |
| West German Cancer Center, Department of Medical Oncology, University Hospital Essen | Essen, Germany, Germany | Recruiting |
| Erasmus Universitair Medisch Centrum Rotterdam Department of Pulmonary Medicine | Rotterdam, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06784791